Overview
Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death
Status:
Terminated
Terminated
Trial end date:
2011-04-01
2011-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Recent ACC/AHA/ESC guidelines recommend prophylactic ICD implantation in most patients with coronary heart disease and LVEF < 40%. Current Canadian guidelines recommend ICDs for primary prophylaxis in CAD patients with LVEF < 30% (Class I recommendation). There are very sparse data to recommend ICD implantation in patients with EF between 30 and 40 %. This study will randomize patients with CHD and an EF between 30 and 40% to ICD therapy vs. No ICD therapy. The primary outcome is mortality and the study is powered as a non-inferiority trial to test the hypothesis that mortality in patients with no ICD is not more than 1% greater (absolute yearly increase) than patients receiving an ICD.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
St. Michael's Hospital, Toronto
Unity Health TorontoCollaborators:
Institute for Clinical Evaluative Sciences
Ontario Ministry of Health and Long Term Care
Criteria
Inclusion Criteria:- documented chronic coronary heart disease (prior MI and/or angiographically documented
CAD), > 40 days post the most recent MI;
- LVEF < 40% (by MUGA) and NYHA functional class II or III at time of assessment OR LVEF
≤ 35 % (by MUGA) and NYHA functional class I, II or III at time of assessment
- Judged to have a reasonable expectation of survival with a good functional status for
more than 1 year, as well as receiving optimum, guideline recommended therapy for
coronary artery disease and heart failure (or demonstrated intolerance or
contraindications to such therapy).
- Age ≥ 18 years; no upper age limitation.
Exclusion Criteria:
- Prior cardiac arrest, sustained VT or VF, or unexplained syncope.
- Attempted VT / VF induction at electrophysiological study.
- Need for a cardiac resynchronization therapy (CRT) device.
- Enrollment in another interventional trial.